Skip to main content
. 2014 Aug 12;22(9):1614–1624. doi: 10.1038/mt.2014.131

Figure 3.

Figure 3

Increased therapeutic efficiency using the hyperactive PB platform. CB17/IcrTac/Prkdcscid mice were hydrodynamically transfected with (a,c,e) 500 ng or (b,d,f) 50 ng of PB-hFIXco (a–f), (c,d; triangle) PB-hFIXco/IRmicro or (e,f, triangle) PB-hFIXco/IR mut16 transposon plasmids along with (a,c) 1,000 ng or (b,d) 100 ng mPB (triangle a,b) or hyPB-expressing plasmid (square a,b) or empty control plasmid (hatched lines). hFIX expression was measured on plasma samples collected at the indicated times by a specific enzyme-linked immunosorbent assay assay. Results were presented as mean ± SEM. n.s. indicates not significant; *P < 0.05; **P < 0.01; ***P < 0.001 (n = 3 mice/group).